Advocacy Webpage Graphics Teach It
TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma
Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of individualized addiction treatment so that more patients receive high-quality, evidence-based care
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to comprehensive, high-quality addiction care

Leading the movement to transform America's addiction treatment infrastructure and expand access to research-validated, results-based care


ASAM Policy Principles

ASAM believes in a future in which addiction prevention, treatment, remission, and recovery are accessible to all, and where they profoundly improve the health of all people. The following principles guide our advocacy and shape ASAM's advocacy priorities:
  • Addiction policy should be guided by - and promote the use of - the latest science and best practices in addiction prevention, treatment, remission, and recovery.  People with addiction deserve compassionate, evidence-based care that addresses the chronic nature of the disease of addiction.
  • Strategic and multifaceted policy solutions are needed to drive the development of a more accessible, effective, robust, and comprehensive addiction prevention and treatment infrastructure.
  • Policies and payment systems should ensure equitable access to comprehensive, high-quality addiction prevention, treatment, and recovery services.
  • Policy should challenge, rather than enforce, cultural misunderstanding, stigma and discrimination about the disease of addiction.
  • Addiction policy and advocacy should respect and integrate the perspectives of people with addiction and their families.

ASAM Joins the Friends of NIDA in Expressing Support for the Medical Marijuana Research Act

by | Jul 19, 2019


On July 17, Representatives Andy Harris (R-MD), Earl Blumenauer (D-OR), Zoe Lofgren (D-CA), H. Morgan Griffith (R-VA), Debbie Dingell (D-MI), and Rob Bishop (R-UT) introduced the Medical Marijuana Research Act of 2019, which would reduce many of the burdensome barriers researchers face when conducting legitimate scientific research involving cannabis. ASAM endorsed the bill in a letter from the Friends of NIDA. There is a growing body of research that indicates cannabis has the potential to effectively treat certain medical conditions. However, there is also significant evidence that consistent use of cannabis can have deleterious effects on a patient’s health. ASAM is pleased to endorse this bill, as it will serve to generate research that can better inform policymakers when legislating on this issue.


This bill would create an exception for cannabis from the current obstacles of Schedule I registration and review procedures. It would furthermore require that the Department of Justice approve applications from individuals seeking to manufacture or dispense cannabis for legitimate medical research unless such a registration is not in the public interest. Finally, the bill would require that the Department of Health and Human Services review existing medical and other research on cannabis and report the findings to Congress. Through these measures, the Medical Marijuana Research Act would streamline research efforts into cannabis while also better educating Congress on the current body of research pertaining to cannabis.  


Read the bill text here.


Read the Friends of NIDA Letter here.